Shukun Technology Receives CSRC Approval to Proceed with H-Share IPO; Set to Update Prospectus

According to the public announcement made by the China Securities Regulatory Commission (CSRC) on March 18, SHUKUN, a leading medical AI company, has received formal approval from the CSRC for its H-share listing application. The approval is valid for 12 months from the date of issuance.

Industry insiders stated that the CSRC’s approval, commonly known as the “green light,” signifies that SHUKUN has successfully completed the domestic regulatory procedures required for its H-share listing.

It is understood that SHUKUN submitted its prospectus to the Hong Kong Stock Exchange on September 21, 2021. As the six-month validity period has just expired, the prospectus has lapsed. However, under HKEX regulations, the company can maintain its review status by promptly filing a new version of the prospectus with updated data, thereby allowing it to wait for an appropriate market window to proceed with its listing efforts.

Founded in 2017, SHUKUN is a global leader in providing AI-powered medical solutions for disease screening, diagnosis, and treatment selection and planning. SHUKUN’s “Digital Doctor” product portfolio comprises 12 commercialized products and 25 pipeline candidates, covering five key therapeutic areas: cardiovascular, cerebrovascular, abdominal, thoracic, and musculoskeletal systems. The company has obtained two Class III medical device registration certificates and eleven Class II medical device registration certificates from the National Medical Products Administration (NMPA), as well as four MDR CE certifications. According to a third-party Frost & Sullivan report, SHUKUN ranks first globally in the industry by the number of regulatory approvals obtained.